30-Second Takeaway
- Uncontrolled hypertension and alcohol-related complications remain highly prevalent, driving inpatient morbidity and costs.
- Semaglutide appears cost-effective for secondary CVD prevention at reduced prices but substantially raises health spending at current costs.
- Intensive lifestyle change remains the dominant strategy for diabetes prevention among U.S. adults with prediabetes.
- Current CGM performance in inpatient hypoglycemia is too inaccurate to guide therapy without confirmatory capillary testing.
- Low-touch system nudges (PDMP emails, EDI programs) can shift behaviors and diversity metrics but do not guarantee clinical outcome change.
Week ending February 7, 2026
Clinical levers and limits: hypertension control, cardiometabolic prevention, and evolving inpatient risks
NHANES 2021–2023 shows substantial residual uncontrolled hypertension in U.S. adults
Using 2021–2023 NHANES data, this study quantified the proportion of U.S. adults with hypertension whose blood pressure remains above guideline goals. Findings indicate a large burden of uncontrolled blood pressure despite widespread treatment availability. These updated national estimates have direct implications for quality metrics and population-level cardiovascular risk reduction strategies. Outpatient systems may need more aggressive treatment intensification, adherence support, and home monitoring to close this control gap.
Semaglutide for secondary CVD prevention is conditionally cost-effective but expensive at current prices
A U.S. CVD Policy Model simulation evaluated lifetime semaglutide plus usual care vs usual care alone in adults ≥45 years with obesity, prior MI or stroke, and no diabetes. Among roughly 4 million eligible adults, semaglutide was projected to avert about 358 400 MACE events. At an annual net drug cost of $8604, the incremental cost-effectiveness ratio was $148 100 per QALY, above a $120 000 threshold. Lowering annual cost by 18% to $7055 met the $120 000 per QALY threshold, while a $5988 cash price yielded about $99 600 per QALY. Nationwide adoption at current prices was projected to increase U.S. health care spending by $23 billion annually, challenging affordability despite clinical benefit.
Intensive lifestyle outperforms metformin for 3‑year diabetes prevention in U.S. adults with prediabetes
Using NHANES 2015–2020, this study applied a validated model to estimate 3‑year diabetes risk under different preventive strategies in 2,778 U.S. adults with prediabetes. Predicted diabetes risk was 18.4% with standard lifestyle, 14.4% with metformin, and 8.0% with intensive lifestyle. An individualized “optimal intervention” approach yielded a mean predicted risk of 7.6%, only slightly better than assigning intensive lifestyle to everyone. Intensive lifestyle was the model-selected optimal strategy for 91% of participants. These data support prioritizing structured intensive lifestyle programs as first-line diabetes prevention, reserving metformin for select subgroups or feasibility constraints.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.